Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHV NASDAQ:CDXS NASDAQ:FBIO NASDAQ:SABS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$5.60+2.2%$4.45$2.00▼$6.15$562.57M2.271.31 million shs1.19 million shsCDXSCodexis$2.47-5.4%$2.46$0.96▼$3.87$236.79M2.48784,254 shs1.05 million shsFBIOFortress Biotech$2.93+2.8%$2.49$1.70▼$4.53$94.67M1.22460,904 shs405,012 shsSABSSAB Biotherapeutics$3.36-1.2%$3.73$1.60▼$6.60$259.98M0.54460,123 shs362,646 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences+6.82%+3.40%+5.18%+28.04%+43.08%CDXSCodexis+1.95%-2.25%-8.42%+110.48%+10.13%FBIOFortress Biotech+7.55%+10.89%+19.25%-15.18%+42.50%SABSSAB Biotherapeutics+0.59%-1.16%-17.27%-17.07%+87.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$5.60+2.2%$4.45$2.00▼$6.15$562.57M2.271.31 million shs1.19 million shsCDXSCodexis$2.47-5.4%$2.46$0.96▼$3.87$236.79M2.48784,254 shs1.05 million shsFBIOFortress Biotech$2.93+2.8%$2.49$1.70▼$4.53$94.67M1.22460,904 shs405,012 shsSABSSAB Biotherapeutics$3.36-1.2%$3.73$1.60▼$6.60$259.98M0.54460,123 shs362,646 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences+6.82%+3.40%+5.18%+28.04%+43.08%CDXSCodexis+1.95%-2.25%-8.42%+110.48%+10.13%FBIOFortress Biotech+7.55%+10.89%+19.25%-15.18%+42.50%SABSSAB Biotherapeutics+0.59%-1.16%-17.27%-17.07%+87.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHVAchieve Life Sciences 3.00Buy$14.67161.90% UpsideCDXSCodexis 2.00Hold$5.00102.43% UpsideFBIOFortress Biotech 2.25Hold$17.00480.20% UpsideSABSSAB Biotherapeutics 2.80Moderate Buy$11.00227.38% UpsideCurrent Analyst Ratings BreakdownLatest FBIO, ACHV, CDXS, and SABS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026ACHVAchieve Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026CDXSCodexis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026SABSSAB Biotherapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.005/20/2026SABSSAB Biotherapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.005/20/2026SABSSAB Biotherapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.005/18/2026FBIOFortress Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/12/2026SABSSAB Biotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $10.005/11/2026SABSSAB Biotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/11/2026SABSSAB Biotherapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.005/8/2026ACHVAchieve Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/8/2026CDXSCodexis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHVAchieve Life SciencesN/AN/AN/AN/A$0.40 per shareN/ACDXSCodexis$70.39M3.19N/AN/A$0.56 per share4.41FBIOFortress Biotech$63.26M1.54N/AN/A$2.00 per share1.47SABSSAB Biotherapeutics$1.32M194.63$0.34 per share9.95$3.18 per share1.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHVAchieve Life Sciences-$54.65M-$1.12N/AN/AN/AN/A-193.49%-111.88%8/6/2026 (Estimated)CDXSCodexis-$43.97M-$0.37N/AN/AN/A-40.97%-68.09%-23.72%8/12/2026 (Estimated)FBIOFortress Biotech$6.82M$3.170.921.94N/A193.12%109.66%45.56%8/13/2026 (Estimated)SABSSAB Biotherapeutics$13.27M-$2.11N/AN/AN/AN/A-0.29%-0.25%8/6/2026 (Estimated)Latest FBIO, ACHV, CDXS, and SABS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026FBIOFortress Biotech-$0.22$2.82+$3.04$2.82$16.34 million$16.04 million5/12/2026Q1 2026ACHVAchieve Life Sciences-$0.30-$0.19+$0.11-$0.19N/AN/A5/12/2026Q1 2026SABSSAB Biotherapeutics-$0.20-$0.35-$0.15-$0.35$0.13 millionN/A5/7/2026Q1 2026CDXSCodexis-$0.11-$0.10+$0.01-$0.10$14.53 million$15.25 million3/31/2026Q4 2025FBIOFortress Biotech$0.11-$0.21-$0.32-$0.21$26.17 million$16.08 million3/24/2026Q4 2025ACHVAchieve Life Sciences-$0.27-$0.28-$0.01-$0.28N/AN/A3/11/2026Q4 2025CDXSCodexis$0.01$0.11+$0.10$0.11$35.83 million$38.92 million3/9/2026Q4 2025SABSSAB Biotherapeutics-$0.16-$0.46-$0.30-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACHVAchieve Life SciencesN/AN/AN/AN/AN/ACDXSCodexisN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/ASABSSAB BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHVAchieve Life Sciences0.872.622.62CDXSCodexis0.945.365.23FBIOFortress Biotech0.182.862.77SABSSAB Biotherapeutics0.0111.4511.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHVAchieve Life Sciences33.52%CDXSCodexis78.54%FBIOFortress Biotech96.51%SABSSAB Biotherapeutics7.82%Insider OwnershipCompanyInsider OwnershipACHVAchieve Life Sciences3.00%CDXSCodexis3.50%FBIOFortress Biotech28.50%SABSSAB Biotherapeutics25.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHVAchieve Life Sciences20102.66 million99.58 millionOptionableCDXSCodexis25090.90 million87.72 millionOptionableFBIOFortress Biotech17033.22 million23.75 millionOptionableSABSSAB Biotherapeutics14076.46 million57.30 millionNot OptionableFBIO, ACHV, CDXS, and SABS HeadlinesRecent News About These CompaniesSAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual MeetingMay 29, 2026 | finance.yahoo.comSAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual MeetingMay 29, 2026 | globenewswire.comCitigroup initiates coverage of SAB Biotherapeutics (SABS) with buy recommendationMay 23, 2026 | msn.comWhy SAB Biotherapeutics, Inc.’s (SABS) Stock Is Up 7.01%May 21, 2026 | aaii.comASAB Biotherapeutics Inc SABSMay 20, 2026 | morningstar.comMJefferies initiates coverage of SAB Biotherapeutics (SABS) with buy recommendationMay 20, 2026 | msn.comSAB Biotherapeutics Signs Manufacturing Pact for SAB-142May 16, 2026 | theglobeandmail.comWe Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth CarefullyMay 16, 2026 | finance.yahoo.comSAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...May 12, 2026 | finance.yahoo.comSAB Biotherapeutics Q1 Earnings Call HighlightsMay 12, 2026 | marketbeat.comSAB BIO Reports Q1 2026 Financial Results and Recent Business HighlightsMay 12, 2026 | globenewswire.comSAB Biotherapeutics (NASDAQ:SABS) Given Buy Rating at Rodman & RenshawMay 11, 2026 | marketbeat.comSAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ETMay 5, 2026 | globenewswire.comEmergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB ...April 29, 2026 | caledonianrecord.comCSAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026April 22, 2026 | globenewswire.comSAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 DiabetesApril 15, 2026 | seekingalpha.comSAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society CongressApril 15, 2026 | markets.businessinsider.comSAB Biotherapeutics closes $85 million public offeringMarch 20, 2026 | thepharmaletter.comTSAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsMarch 19, 2026 | globenewswire.comSAB Biotherapeutics Launches Major Equity Financing OfferingMarch 19, 2026 | tipranks.comSAB Biotherapeutics, Inc. Prices Public Offering of Common Stock and Pre-Funded Warrants to Raise Approximately $85 MillionMarch 17, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFBIO, ACHV, CDXS, and SABS Company DescriptionsAchieve Life Sciences NASDAQ:ACHV$5.60 +0.12 (+2.19%) Closing price 04:00 PM EasternExtended Trading$5.51 -0.09 (-1.68%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.Codexis NASDAQ:CDXS$2.47 -0.14 (-5.36%) As of 04:00 PM EasternCodexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Fortress Biotech NASDAQ:FBIO$2.93 +0.08 (+2.81%) Closing price 04:00 PM EasternExtended Trading$2.95 +0.02 (+0.65%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.SAB Biotherapeutics NASDAQ:SABS$3.36 -0.04 (-1.18%) Closing price 04:00 PM EasternExtended Trading$3.37 +0.01 (+0.30%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
